Cardiac implants are devices that are implanted in the heart tissue, in order to control irregular heart function. Cardiac implants such as pacemakers, defibrillator implants, and cardiac rhythm monitoring implants are available in the market to treat cardiac dysfunction such as heart rhythm disorders, arrhythmias and other heart related disorder. These cardiac implants market are majorly prescribed to patients with heart failure.

Cardiac implants have been developed with innovative technical features in recent years which has improved quality of life in patients with heart failure. For instance, technologically advanced cardiac implants such as HeartWare HVAD Pump (HeartWare), Parachute Ventricular Partitioning Device (CardioKinetix Inc.), and Quadra Assura MP (St. Jude Medical, Inc.) are currently available in the market. Thus, technological advancements in implantable cardiac devices is propelling the cardiac implant market growth.

Request A Sample Copy: http://bit.ly/31vJr3x

Increasing focus of manufacturers on development and introduction of highly advanced implantable devices aimed at improving patient outcome, is expected to drive growth of the cardiac implant market. For instance, in April 2016, St. Jude Medical, Inc. launched the Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) in the U.S market. The company was later acquired by Abbott in January 2017.

Moreover, regulatory approvals for cardiac implantable devices is expected to drive growth of the cardiac implant market. For instance, in April 2016, the U.S. Food and Drug Administration approved the first pacemaker, Micra Transcatheter Pacing System, developed by Medtronic Plc Plc. The system does not require wired leads to establish an electric connection between the pulse-generating device and the heart. The device functions like a pacemaker to regulate heart rate. The device is implanted directly in the right ventricle chamber of the heart.

Increasing regulatory approval for cardiac implants is expected to drive growth of the global cardiac implant market

Most of the hospitals and healthcare organizations indicates cardiovascular implants in patients at risk of cardiac disorder, in order to provide artificial control on the patient’s heart beat in the long term. Increasing number of regulatory approvals for innovative and advanced cardiac implant devices is expected to facilitate growth of the cardiac market in the near future. For instance, in February 2017, Abbott received the U.S. Food and Drug Administration approval for its Assurity MRI pacemaker, which is the smallest, long-lasting wireless MRI-compatible pacemaker. Patients implanted with Assurity MRI pacemaker can undergo full body magnetic resonance imaging (MRI) scans, if required.

Moreover, rising incidence of cardiovascular diseases around the world is expected to boost growth of the cardiac implant market over the forecast period. According to the World Health Organization, in 2015, around 17.7 million deaths were caused by cardiovascular diseases, out of which around 7.4 million deaths were caused due to coronary heart disease, and 6.7 million deaths due to stroke.

Cardiac Implant Market- Restraints

Infections associated with implantable pacemakers in cardiac patients is likely to dissuade patients from opting for these products, which may restrain demand for cardiac implants. For instance, according to Medtronic Plc, risks associated with an implantable cardioverter defibrillators (ICD) implant include surgical site infections, sensitivity to the device material, failure to deliver therapy when it is needed, and receiving extra therapy when it is not needed. Moreover, after receiving an ICD therapy, patient will have limitations with respect to electromagnetic and magnetic radiation.

Cardiac Implant Market- Regional Analysis

Regional segmentation of the global cardiac implant market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold a dominant position in the market, owing to rising demand for pacemakers. According to the American Heart Association (AHA), 2017, around 92.1 million adults in the U.S. are suffering from some form of cardiovascular disease, or after-effects of stroke. The AHA report also stated that direct and indirect costs of cardiovascular diseases and stroke are estimated to account for US$ 316 billion, including health expenditures and lost productivity.

The Asia Pacific cardiac implant market is expected to witness significant growth during the forecast period owing to increasing preference for technologically advanced products for cardiac rhythm management, coupled with rising healthcare concerns for stroke prevention associated with atrial fibrillation. According to the Japanese Heart Rhythm Society, in 2017, the Asian population with atrial fibrillation (AF) is estimated to reach 72 million by 2050, of which 2.9 million may suffer from AF-associated strokes.

Europe is expected to show significant growth rate, owing to rising number of approvals by the European Drug regulatory authorities for cardiac implants for various purposes. For instance, in 2015, EBR Systems received the CE marking for its WiSE leadless pacemaker. The device is intended to improve the left ventricular function. Moreover, in February 2017, Medtronic Plc. received the CE marking for a suite of quadripolar cardiac resynchronization therapy pacemakers (CRT-Ps) that also allow patients to receive MRI (magnetic resonance imaging) scans.

Cardiac Implant Market - Competitive Landscape

Key players operating in the global cardiac implant market include Medtronic Plc. BIOTRONIK, Inc., Boston Scientific Corporation, Abbott Laboratories, Vitatron Holding B.V., Shree Pacetronix Ltd., MEDICO S.p.A., Lepu Medical Technology Co Ltd., LivaNova PLC, and Qinming Medical, and Cordis Inc.

Click To Read More On: Cardiac Implants Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:[email protected]